• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心肺疾病中的内皮素:旁分泌因子与神经体液因子

Endothelin in cardiopulmonary disease: factor paracrine vs neurohumoral.

作者信息

Stewart D J

机构信息

McGill University, McGill Vascular Biology Group, Royal Victoria Hospital, Montreal, Quebec, Canada.

出版信息

Eur Heart J. 1993 Nov;14 Suppl I:48-54.

PMID:7904941
Abstract

Endothelin-1 is a potent endothelium-derived vasoconstrictor peptide which also has important growth promoting effects on other cellular elements of the vascular wall. Increased local expression and release of endothelin-1 may therefore contribute to abnormal vascular tone and structure in paracrine fashion. Evidence of increased pulmonary production of endothelin-1 by the lung in patients with primary pulmonary hypertension is reviewed, including increased release across the pulmonary circulation and increased vascular expression of the peptide and its mRNA. However, circulating endothelin-1 might also have a humoral action on distant vascular beds. Changes in plasma endothelin-1 in response to postural change and chronic heart failure support a role for this potent vasoconstrictor factor in the neurohumoral response to haemodynamic stress. Thus, like other vascular regulatory mechanisms, the endothelin system might play a dual role in the control of vascular function with both local tissue and circulatory components.

摘要

内皮素-1是一种强效的内皮源性血管收缩肽,对血管壁的其他细胞成分也具有重要的促生长作用。因此,内皮素-1局部表达和释放增加可能以旁分泌方式导致血管张力和结构异常。本文综述了原发性肺动脉高压患者肺组织中内皮素-1生成增加的证据,包括经肺循环释放增加以及该肽及其信使核糖核酸的血管表达增加。然而,循环内皮素-1对远处血管床也可能具有体液作用。体位改变和慢性心力衰竭时血浆内皮素-1的变化支持这种强效血管收缩因子在对血流动力学应激的神经体液反应中发挥作用。因此,与其他血管调节机制一样,内皮素系统在血管功能调控中可能通过局部组织和循环成分发挥双重作用。

相似文献

1
Endothelin in cardiopulmonary disease: factor paracrine vs neurohumoral.心肺疾病中的内皮素:旁分泌因子与神经体液因子
Eur Heart J. 1993 Nov;14 Suppl I:48-54.
2
Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.内皮素-1在肺动脉高压患者肺组织中的表达。
N Engl J Med. 1993 Jun 17;328(24):1732-9. doi: 10.1056/NEJM199306173282402.
3
[Level of endothelin increases in chronic congestive heart failure].[慢性充血性心力衰竭时内皮素水平升高]
Kardiol Pol. 1993 Mar;38(3):169-72; discussion 173.
4
Effects of peptide vasoconstrictors on vessel structure.肽类血管收缩剂对血管结构的影响。
Am J Med. 1993 Apr 23;94(4A):13S-19S.
5
[The endothelial cell as an endocrine organ--endothelin].[作为内分泌器官的内皮细胞——内皮素]
Tidsskr Nor Laegeforen. 1992 Feb 20;112(5):648-52.
6
[Participation of endothelium-derived vasoconstrictor factors in arterial hypertension].[内皮源性血管收缩因子在动脉高血压中的作用]
Rev Esp Cardiol. 1999;52 Suppl 3:4-11.
7
Endothelin: role in hypertension.内皮素:在高血压中的作用
Biol Res. 1998;31(3):199-208.
8
Role of endothelin in cardiovascular disease.内皮素在心血管疾病中的作用。
J Renin Angiotensin Aldosterone Syst. 2002 Mar;3(1):1-15. doi: 10.3317/jraas.2002.001.
9
Update on endothelin.内皮素的最新进展。
Can J Cardiol. 1998 Jul;14 Suppl D:11D-13D.
10
Endothelial dysfunction in pulmonary vascular disorders.肺血管疾病中的内皮功能障碍。
Arzneimittelforschung. 1994 Mar;44(3A):451-4.

引用本文的文献

1
LU135252, an endothelin(A) receptor antagonist did not prevent pulmonary vascular remodelling or lung fibrosis in a rat model of myocardial infarction.内皮素(A)受体拮抗剂LU135252在心肌梗死大鼠模型中未能预防肺血管重塑或肺纤维化。
Br J Pharmacol. 2000 Aug;130(7):1525-30. doi: 10.1038/sj.bjp.0703466.
2
Endothelin receptors in human coronary artery and aorta.人类冠状动脉和主动脉中的内皮素受体
Br J Pharmacol. 1996 Mar;117(5):986-92. doi: 10.1111/j.1476-5381.1996.tb15292.x.
3
Altered responsiveness to endothelin-1 of myocardium from pacing-induced heart failure model in the dog.
Cardiovasc Drugs Ther. 1996 May;10(2):107-12. doi: 10.1007/BF00823587.
4
The clinical potential of endothelin receptor antagonists in cardiovascular medicine.内皮素受体拮抗剂在心血管医学中的临床潜力。
Drugs. 1996 Jan;51(1):12-27. doi: 10.2165/00003495-199651010-00003.